Development and Characterization of Synthetic Glucopyranosyl Lipid Adjuvant System as a Vaccine Adjuvant

@inproceedings{Coler2011DevelopmentAC,
  title={Development and Characterization of Synthetic Glucopyranosyl Lipid Adjuvant System as a Vaccine Adjuvant},
  author={Rhea N Coler and Sylvie Bertholet and Magdalini Moutaftsi and Jeff A. Guderian and Hillarie Plessner Windish and Susan Baldwin and Elsa M. Laughlin and Malcolm Scott Duthie and Christopher B Fox and Darrick Carter and Martin Howell Friede and Thomas S. Vedvick and Steven G Reed},
  booktitle={PloS one},
  year={2011}
}

• Rhea N Coler, Sylvie Bertholet, +10 authors Steven G Reed
• Published in PloS one 2011
• DOI:10.1371/journal.pone.0016333

Innate immune responses to vaccine adjuvants based on lipopolysaccharide (LPS), a component of gram-negative bacterial cell walls, are driven by Toll-like receptor (TLR) 4 and adaptor proteins including MyD88 and TRIF, leading to the production of inflammatory cytokines, type I interferons, and chemokines. We report here on the characterization of a synthetic hexaacylated lipid A derivative, denoted as glucopyranosyl lipid adjuvant (GLA). We assessed the effects of GLA on murine and human… CONTINUE READING

View PDF

Save to Library

Create Alert

Cite